The IT Law Wiki
(Created page with "== Overview == On November 12 and 13, 2009, the Food and Drug Administration (FDA) held a public meeting titled '''Promotion of FDA-Regulated Medical Products Using the ...")
 
 
(5 intermediate revisions by the same user not shown)
Line 1: Line 1:
 
== Overview ==
 
== Overview ==
   
On November 12 and 13, 2009, the [[Food and Drug Administration]] ([[FDA]]) held a public meeting titled '''Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools''' to discuss issues related to the promotion of FDA-regulated medical products on the Internet and social media tools.
+
On November 12 and 13, 2009, the [[Food and Drug Administration]] ([[FDA]]) held a public meeting titled '''Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools''' to discuss issues related to the promotion of [[FDA]]-regulated medical products on the [[Internet]] and [[social media tools]].
   
The following issues were identified: responding to unsolicited requests; fulfilling regulatory requirements when using tools associated with space limitations; fulfilling post-marketing submission requirements; [[online]] [[communication]]s for which manufacturers, packers, or distributors are accountable; use of [[link]]s on the [[Internet]]; and correcting [[misinformation]].
+
The following issues were identified: responding to unsolicited requests; fulfilling regulatory requirements when using [[social media tools|tools]] associated with space limitations; fulfilling post-marketing submission requirements; [[online]] [[communication]]s for which manufacturers, packers, or distributors are accountable; use of [[link]]s on the [[Internet]]; and correcting [[misinformation]].
  +
  +
Following the hearing, the [[FDA]] and solicited written comments through a public docket that was open from September 2009 to February 2010.
  +
  +
Following this meeting the [[FDA]] did not issue any guidelines, but stated that it would "look at [Internet] issues on a case-by-case basis," while reserving the right to revaluate the need for regulations in the future.<ref>''See'' The Pink Sheet (Nov. 8, 1999), at 22 (Statement of Melissa Moncavage, DDMAC Public Health Advisor, at Drug Information Association conference on Oct. 23, 1999).</ref>
  +
  +
== References ==
  +
<references />
   
 
== See also ==
 
== See also ==
Line 9: Line 16:
 
* [[Promotion of FDA-Regulated Medical Products on the Internet]].
 
* [[Promotion of FDA-Regulated Medical Products on the Internet]].
   
== External links ==
+
== External references ==
   
 
* [http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM193462.pdf Transcript of Day 1] (Nov. 12, 2009).
 
* [http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM193462.pdf Transcript of Day 1] (Nov. 12, 2009).
 
* [http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM193463.pdf Transcript of Day 2] (Nov. 13, 2009).
 
* [http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM193463.pdf Transcript of Day 2] (Nov. 13, 2009).
  +
[[Category:Medical]]
  +
[[Category:Advertising]]
  +
[[Category:Internet]]
  +
[[Category:Social media]]
  +
[[Category:FDA]]
  +
[[Category:2009]]

Latest revision as of 14:49, 27 June 2014

Overview[]

On November 12 and 13, 2009, the Food and Drug Administration (FDA) held a public meeting titled Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools to discuss issues related to the promotion of FDA-regulated medical products on the Internet and social media tools.

The following issues were identified: responding to unsolicited requests; fulfilling regulatory requirements when using tools associated with space limitations; fulfilling post-marketing submission requirements; online communications for which manufacturers, packers, or distributors are accountable; use of links on the Internet; and correcting misinformation.

Following the hearing, the FDA and solicited written comments through a public docket that was open from September 2009 to February 2010.

Following this meeting the FDA did not issue any guidelines, but stated that it would "look at [Internet] issues on a case-by-case basis," while reserving the right to revaluate the need for regulations in the future.[1]

References[]

  1. See The Pink Sheet (Nov. 8, 1999), at 22 (Statement of Melissa Moncavage, DDMAC Public Health Advisor, at Drug Information Association conference on Oct. 23, 1999).

See also[]

External references[]